Cadila Pharmaceuticals Introduces Innovative Quadrivalent Influenza Vaccine

Ahmedabad,  March  04, 2024: Cadila Pharmaceuticals, a  pioneer  in  the  pharmaceutical  industry, proudly  announces  the  launch  of  the  Cadiflu  Tetra  Vaccine  –  an  advanced  Quadrivalent  Influenza  Vaccine  to  prevent influenza, a recurrent, widespread and debilitating viral infection.  The vaccine is approved by DCGI for use in adults and children. 

Cadiflu  Tetra  Vaccine  targets  four  strains  of  the  Influenza  virus  subtype–A  and  B,  responsible  for seasonal  epidemics.  Developed  using  cutting-edge  proprietary  technology  employing  Nano-sized particles,  the  vaccine  mimics  the  external  structure  of  the  virus  without  containing  intact  genetic material. 

The  vaccine  carries  hemagglutinin  (HA),  neuraminidase  (NA)  and  matrix  1  (M1)  proteins  from  the respective  strains  aggregated  together  in  a  single  formulation.  The  VLP  vaccine  replicates  external structure of the viruses but does not contain any live genetic substance, which can cause viral replication and infection. Therefore, this vaccine is qualitatively superior and has better safety profile. 

Dr. Rajiv I. Modi, Chairman and Managing Director, Cadila Pharmaceuticals, stated, “Our commitment to advancing healthcare has led us to develop the Cadiflu Tetra Vaccine, a testament to our dedication to addressing the evolving needs of patients globally, using next generation technology. Influenza is a global concern, and our goal is to provide a robust solution that not only protects vulnerable population but also contributes to overall strengthening of public health defence against influenza outbreaks.” 

The Cadiflu Tetra Vaccine aims to reduce the incidence of influenza illness, mitigate the severity of the disease  in  affected  individuals,  and  decrease  the  transmission  of  the  infection  to  others.  This breakthrough  in  vaccine  development  also  holds  promise  for  enhancing  the  protection  of  pregnant women against influenza, contributing to the overall well-being of both mother and child. 

Influenza, commonly known as seasonal flu, is a highly contagious acute respiratory illness caused by influenza viruses. These incidents can occur globally at any time of the year, often involving multiple waves lasting for extended periods. 

Cadila  Pharmaceuticals  remains  committed  to  pushing  the  boundaries  of  medical  innovation  and improving  public  health.  The  introduction  of  the  Cadiflu  Tetra  Vaccine  underscores  the  company’s dedication to providing effective and safe solutions for healthcare challenges, through next generation technologies, particularly in the context of emerging viral illnesses of public health importance.

Corporate Comm India (CCI Newswire)